Phase II Randomized, Double-Blind Study of mFOLFIRINOX Plus Ramucirumab Versus mFOLFIRINOX Plus Placebo in Advanced Pancreatic Cancer Patients: Hoosier Cancer Research Network GI14-198

Trial Profile

Phase II Randomized, Double-Blind Study of mFOLFIRINOX Plus Ramucirumab Versus mFOLFIRINOX Plus Placebo in Advanced Pancreatic Cancer Patients: Hoosier Cancer Research Network GI14-198

Recruiting
Phase of Trial: Phase II

Latest Information Update: 23 Aug 2017

At a glance

  • Drugs Ramucirumab (Primary) ; Fluorouracil; Irinotecan; Oxaliplatin
  • Indications Pancreatic cancer
  • Focus Therapeutic Use
  • Most Recent Events

    • 10 Aug 2016 Status changed from not yet recruiting to recruiting.
    • 19 Jan 2016 Planned primary completion date changed from 1 Dec 2018 to 1 Mar 2018, as reported by ClinicalTrials.gov.
    • 19 Jan 2016 Planned initiation date changed from 1 Dec 2015 to 1 Mar 2016, as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top